Key result
Saxagliptin significantly decreased NPY3-36 concentrations during moderate intensity exercise compared to placebo, without affecting hemodynamics or catecholamine concentrations.
Why the study?
The secretions of NPY1–36 and NPY3–36 in response to sympathetic nervous system activation had not been studied due to a lack of analytical techniques to distinguish them.
Does saxagliptin alter neuropeptide Y and catecholamine kinetics or physiological responses during moderate and heavy intensity exercises in healthy male volunteers?
Population
Six healthy males
Comparison
Saxagliptin vs placebo
Design
Randomized, double-blind crossover study
Authors
Loading...
No hemodynamic effects despite NPY changes; extends DPP4-NPY mechanisms in healthy volunteers but leaves patient relevance open.
RCT (n=6)
Double-blind
Randomized crossover
No
Does saxagliptin alter neuropeptide Y and catecholamine kinetics or physiological responses during moderate and heavy intensity exercises in healthy male volunteers?
Absolute Event Rate: 4.01% vs 13%
p-value: p=<0.001
DPP4 inhibition with saxagliptin alters the NPY1-36/NPY3-36 ratio but does not affect catecholamine release or hemodynamic responses during exercise in healthy volunteers.
Eugster et al. (2022) conducted an RCT in Healthy volunteers (n=6). Saxagliptin vs. Placebo was evaluated on NPY3-36 concentration (AUC0-15min) during moderate intensity exercise (pM × min) (p=<0.001). Saxagliptin significantly decreased NPY3-36 concentrations during moderate intensity exercise compared to placebo, without affecting hemodynamics or catecholamine concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: